Table 2.

Demographic and clinical characteristics of the PRL+ and PRL− relapsing pwRRMS.

Demographic and clinical characteristics	PRL+ (n=12)	PRL− (n=9)	p-value
At baseline timepoint
Age, mean ± SD	39.2 ± 6.8	39.8 ± 9.8	0.874a
Sex	7 female, 5 male	8 female, 1 male	0.178b
Disease Duration in years, mean ± SD	8.3 ± 5.6	9.8 ± 6.9	0.613a
Years of Education, mean ± SD	14.9 ± 2.1	15.6 ± 1.7	0.639a
EDSS, median (IQR)	2.5 [1 – 6.5]	1.5 [1.0 - 6.5]	0.537c
Medication, % (n/n)			0.126b
High efficacy	25.0% (3/12)	15.8% (1/9)
Low/moderate efficacy	33.3% (4/12)	11.1% (7/9)
None	41.7% (5/12)	11.1% (1/9)
At the relapse timepoint
T2 LV, mean ± SD	12.4 ± 7.4	6.8 ± 6.5	0.082a

pwRRMS – people with relapsing-remitting multiple sclerosis, EDSS – Expanded Disability Status Scale, LV – lesion volume, PRL – paramagnetic rim lesion, SD – standard deviation, IQR – interquartile range.

P-values lower than 0.05 were considered statistically significant and shown in bold. T2 is shown in milliliters (mL). “Low/moderate” efficacy medications included dimethyl fumerate, glatiramer acetate, and interferon beta-1a. “High” efficacy medications included natalizumab and fingolimod.

^aIndependent-samples t-test

^bChi-square test, and

^cMann-Whitney U test.